Insulinemia, heterogeneity of obesity and the risk of different types of endometrial cancer: existing evidence

References

• Sheikh MA, Althouse AD, Freese KF, et al. USA Endometrial Cancer Projections to 2030: should we be concerned? Future Oncology. 2014;10(16):2561–2568.
   PubMed Web of Science ®Google Scholar
• Saltiel AR. Insulin resistance in the defense against obesity. Cell Metab. 2012;15(6):798–804.
   PubMed Web of Science ®Google Scholar
• Friedenreich CM, Langley AR, Speidel TP, et al. Case-control study of markers of insulin resistance and endometrial cancer risk. Endocr Relat Cancer. 2012;19(6):785–792.
   PubMed Web of Science ®Google Scholar
• Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International DiabetesFederation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–1645.
   PubMed Web of Science ®Google Scholar
• Godsland IF. Insulin resistance and hyperinsulinaemia in the development and progression of cancer. Clin Sci (Lond). 2009;118(5):315–332.
   PubMed Web of Science ®Google Scholar
• Belfiore A, Malaguarnera R. Insulin receptor and cancer. Endocr Relat Cancer. 2011;18(4):R125–47.
   PubMed Web of Science ®Google Scholar
• Bruchim I, Safrstein R, Werner H. The IGF hormonal network in endometrial cancer: functions, regulation and targeting approach. Front Endocrinol (Lausanne). 2014;5(76):1–10.
   PubMedGoogle Scholar
• Gunter MJ, Hoover DR, Yu H, et al. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(4):921–929.
   PubMed Web of Science ®Google Scholar
• Lukanova A, Zeleniuch-Jacquotte A, Lundin E, et al. Prediagnostic levels of C-peptide, IGF-I, IGFBP -1, -2 and -3 and risk of endometrial cancer. Int J Cancer. 2004;108(2):262–268.
   PubMed Web of Science ®Google Scholar
• Troisi R, Potischman N, Hoover RN, et al. Insulin and endometrial cancer. Am J Epidemiol. 1997;146(6):476–482.
   PubMed Web of Science ®Google Scholar
• Esposito K, Chiodini P, Capuano A, et al. Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine. 2014;45(1):28–36.
   PubMed Web of Science ®Google Scholar
• Berstein LM, Kvatchevskaya JO, Poroshina TE, et al. Insulin resistance, its consequences for the clinical course of the disease, and possibilities of correction in endometrial cancer. J Cancer Res Clin Oncol. 2004;130(11):687–693.
   PubMed Web of Science ®Google Scholar
• Lamon-Fava S. High-density lipoproteins: effects of alcohol, estrogen, and phytoestrogens. Nutr Rev. 2002;60(1):1–7.
   PubMed Web of Science ®Google Scholar
• Nead KT, Sharp SJ, Thompson DJ, et al. Evidence of a causal association between insulinemia and endometrial cancer: a Mendelian randomization analysis. J Natl Cancer Inst. 2015;107(9). pii: djv178. DOI:10.1093/jnci/djv178.
   PubMedGoogle Scholar
• Wang Y, Zhu Y, Zhang L, et al. Insulin promotes proliferation, survival, and invasion in endometrial carcinoma by activating the MEK/ERK pathway. Cancer Lett. 2012;322(2):223–231.
   PubMed Web of Science ®Google Scholar
• Berstein LM, Tchernobrovkina AE, Gamajunova VB, et al. Tumor estrogen content and clinico-morphological and endocrine features of endometrial cancer. J Cancer Res Clin Oncol. 2003;129(4):245–249.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhao D, Gong C, et al. Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis. World J Surg Oncol. 2015;13(1):208.
   PubMed Web of Science ®Google Scholar
• Vishnevsky AS, Bobrov JF, Tsyrlina EV, et al. Hyperinsulinemia as a factor modifying sensitivity of endometrial carcinoma to hormonal influences. Eur J Gynaecol Oncol. 1993;14(2):127–130.
   PubMedGoogle Scholar
• Guo Y, Dang Q. [Estrogen and progesterone receptors in endometrial carcinoma]. Zhonghua Fu Chan Ke Za Zhi. 1997;32(7):418–421. [Article in Chinese]. PMID: 9639729.
   PubMedGoogle Scholar
• Fader AN, Arriba LN, Frasure HE, et al. Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol. 2009;114(1):121–127.
   PubMed Web of Science ®Google Scholar
• Carlson MJ, Thiel KW, Yang S, et al. Catch it before it kills: progesterone, obesity, and the prevention of endometrial cancer. Discov Med. 2012 Sep;14(76):215–222.
   PubMed Web of Science ®Google Scholar
• Renehan AG, Soerjomataram I, Leitzmann MF. Interpreting the epidemiological evidence linking obesity and cancer: a framework for population-attributable risk estimations in Europe. Eur J Cancer. 2010;46(14):2581–2592.
   PubMed Web of Science ®Google Scholar
• Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10–17.
   PubMed Web of Science ®Google Scholar
• Crosbie EJ, Roberts C, Qian W, et al. Body mass index does not influence post-treatment survival in early stage endometrial cancer: results from the MRC ASTEC trial. Eur J Cancer. 2012;48(6):853–864.
   PubMed Web of Science ®Google Scholar
• Canlorbe G, Bendifallah S, Raimond E, et al. Severe obesity impacts recurrence-free survival of women with high-risk endometrial cancer: results of a French Multicenter Study. Ann Surg Oncol. 2015;22(8):2714–2721.
   PubMed Web of Science ®Google Scholar
• Jan S, Duquesne M, Marret H, et al. [Influence of Body Mass Index on management and prognosis of women with endometrial cancer]. Gynecol Obstet Fertil. 2014;42(11):766–771. [Article in French].
   PubMed Web of Science ®Google Scholar
• Anderson B, Connor JP, Andrews JI, et al. Obesity and prognosis in endometrial cancer. Am J Obstet Gynecol. 1996;174(4):1171–1178.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu L, Li C, et al. Correlation analysis between the expressions of leptin and its receptor (ObR) and clinicopathology in endometrial cancer. Cancer Biomark. 2014;14(5):353–359.
   PubMed Web of Science ®Google Scholar
• Wang T, Rohan TE, Gunter MJ, et al. A prospective study of inflammation markers and endometrial cancer risk in postmenopausal hormone nonusers. Cancer Epidemiol Biomarkers Prev. 2011;20(5):971–977.
   PubMed Web of Science ®Google Scholar
• Dallal CM, Brinton LA, Bauer DC, et al. Obesity-related hormones and endometrial cancer among postmenopausal women: a nested case-control study within the B~FIT cohort. Endocr Relat Cancer. 2013;20(1):151–160.
   PubMed Web of Science ®Google Scholar
• Karelis AD, St-Pierre DH, Conus F, et al. Metabolic and body composition factors in subgroups of obesity: what do we know? J Clin Endocrinol Metab. 2004;89:2569–2575.
   PubMed Web of Science ®Google Scholar
• Berstein LM. Cancer and heterogeneity of obesity: a potential contribution of brown fat. Future Oncol. 2012;8(12):1537–1548.
   PubMed Web of Science ®Google Scholar
• Spalding KL, Arner E, Westermark PO, et al. Dynamics of fat cell turnover in humans. Nature. 2008;453:783–787.
   PubMed Web of Science ®Google Scholar
• Lecoultre V, Ravussin E. Brown adipose tissue and aging. Curr Opin Clin Nutr Metab Care. 2011;14(1):1–6.
   PubMed Web of Science ®Google Scholar
• Rosell M, Kaforou M, Frontini A, et al. Brown and white adipose tissues: intrinsic differences in gene expression and response to cold exposure in mice. Am J Physiol Endocrinol Metab. 2014;306(8):E945–E964.
   PubMed Web of Science ®Google Scholar
• Ricquier D. Biology of brown adipose tissue: view from the chair. Int J Obes (Lond). 2010;34(Suppl 1):3–6.
   Web of Science ®Google Scholar
• Esterbauer H, Oberkofler H, Liu YM, et al. Uncoupling protein-1 mRNA expression in obese human subjects: the role of sequence variations at the uncoupling protein-1 gene locus. J Lipid Res. 1998;39(4):834–844.
   PubMed Web of Science ®Google Scholar
• Laky B, Janda M, Cleghorn G, et al. Comparison of different nutritional assessments and body-composition measurements in detecting malnutrition among gynecologic cancer patients. Am J Clin Nutr. 2008;87(6):1678–1685.
   PubMed Web of Science ®Google Scholar
• Zhang C, McFarlane C, Lokireddy S, et al. Inhibition of myostatin protects against diet-induced obesity by enhancing fatty acid oxidation and promoting a brown adipose phenotype in mice. Diabetologia. 2012;55(1):183–193.
   PubMed Web of Science ®Google Scholar
• Smith RC, Lin BK. Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr Opin Support Palliat Care. 2013;7(4):352–360.
   PubMed Web of Science ®Google Scholar
• Sims EA. Are there persons who are obese, but metabolically healthy? Metabolism. 2001;50(12):1499–1504.
   PubMed Web of Science ®Google Scholar
• Samocha-Bonet D, Dixit VD, Kahn CR, et al. Metabolically healthy and unhealthy obese -the 2013 Stock Conference report. Obes Rev. 2014;15(9):697–708.
   PubMed Web of Science ®Google Scholar
• Van Vliet-Ostaptchouk JV, Nuotio ML, et al. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocr Disord. 2014;14:9.
   PubMed Web of Science ®Google Scholar
• Marini MA, Succurro E, Frontoni S, et al. Metabolically healthy but obese women have an intermediate cardiovascular risk profile between healthy nonobese women and obese insulin-resistant women. Diabetes Care. 2007;30(8):2145–2147.
   PubMed Web of Science ®Google Scholar
• Calori G, Lattuada G, Piemonti L, et al. Prevalence, metabolic features, and prognosis of metabolically healthy obese Italian individuals: the Cremona Study. Diabetes Care. 2011;34(1):210–215.
   PubMed Web of Science ®Google Scholar
• Moore LL, Chadid S, Singer MR, et al. Metabolic health reduces risk of obesity-related cancer in Framingham study adults. Cancer Epidemiol Biomarkers Prev. 2014;23(10):2057–2065.
   PubMed Web of Science ®Google Scholar
• Berstein LM, Poroshina TE, Turkevich EA, et al. Features of endometrial cancer in patients with ‘metabolically healthy’ versus ‘standard’ obesity: the decreasing frequency of metabolically healthy obesity. Future Science Open Access. 2015 Sept 4. DOI:10.4155/fso.15.68. [Epub ahead of print].
   Google Scholar
• Schneider D, Halperin R, Langer R, et al. Well-differentiated versus less-differentiated endometrial carcinoma. Eur J Gynaecol Oncol. 1998;19(3):242–245.
   PubMed Web of Science ®Google Scholar
• Villavicencio A, Aguilar G, Acuña J, et al. The identification of two subgroups of obese women with differing endometrial proliferation levels: potential consequences in the development of endometrial cancer. Int J Obes (Lond). 2012;36(7):1012–1015.
   PubMed Web of Science ®Google Scholar
• Rosenblum J, Hendricks CH. Estrogenated vaginal epithelium; relationship to the development of carcinoma of the endometrium. Obstet Gynecol. 1954;3(5):535–545.
   PubMed Web of Science ®Google Scholar
• Berthelsen H, Svane H. Cancer of the endometrium and hyperestrinism; two different modes of origin of endometrial cancer. Dan. Med. Bull. 1956;3(8):236–239.
   PubMedGoogle Scholar
• Bershtein LM. Excretion of classical estrogens and total phenolsteroids in uterine body cancer patients [PhD thesis]. Leningrad: Cand Med Sci; 1967. Available from: http://www.unboundmedicine.com/medline/citation/5599604/
   Google Scholar
• Deligdisch L, Holinka CF. Endometrial carcinoma: two diseases? Cancer Detect Prev. 1987;10(3–4):237–246.
   PubMedGoogle Scholar
• Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod. Pathol. 2000;13(3):295–308.
   PubMed Web of Science ®Google Scholar
• Brinton LA, Felix AS, McMeekin DS, et al. Etiologic heterogeneity in endometrial cancer: evidence from a gynecologic oncology group trial. Gynecol Oncol. 2013;129:277–284.
   PubMed Web of Science ®Google Scholar
• Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control. 2009;16(1):8–13.
   PubMed Web of Science ®Google Scholar
• Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch. 2004;444(3):213–223.
   PubMed Web of Science ®Google Scholar
• Felix AS, Weissfeld JL, Stone RA, et al. Factors associated with Type I and Type II endometrial cancer. Cancer Causes Control. 2010;21(11):1851–1856.
   PubMed Web of Science ®Google Scholar
• Setiawan VW, Yang HP, Pike MC, et al. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol. 2013;31(20):2607–2618.
   PubMed Web of Science ®Google Scholar
• Evans T, Sany O, Pearmain P, et al. Differential trends in the rising incidence of endometrial cancer by type: data from a UK population-based registry from 1994 to 2006. Br J Cancer. 2011;104(9):1505–1510.
   PubMed Web of Science ®Google Scholar
• Murali R, Soslow RA, Weigelt B. Classification of endometrial carcinoma: more than two types. Lancet Oncol. 2014;15(7):e268–e278.
   PubMed Web of Science ®Google Scholar
• Hussein YR, Weigelt B, Levine DA, et al. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. Mod Pathol. 2015;28(4):505–514.
   PubMed Web of Science ®Google Scholar
• Talhouk A, McConechy MK, Leung S, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 2015;113(2):299–310.
   PubMed Web of Science ®Google Scholar
• Lapińska-Szumczyk S, Supernat A, Majewska H, et al. HER2-positive endometrial cancer subtype carries poor prognosis. Clin Transl Sci. 2014;7(6):482–488.
   PubMed Web of Science ®Google Scholar
• Ko EM, Walter P, Clark L, et al. The complex triad of obesity, diabetes and race in Type I and II endometrial cancers: prevalence and prognostic significance. Gynecol Oncol. 2014;133(1):28–32.
   PubMed Web of Science ®Google Scholar
• Trabert B, Wentzensen N, Felix AS, et al. Metabolic syndrome and risk of endometrial cancer in the United States: a study in the SEER–medicare linked database. Cancer Epidemiol Biomarkers Prev. 2015;24(1):261–267.
   PubMed Web of Science ®Google Scholar
• Gargett BE, Chan RW. Endometrial stem/progenitor cells and proliferative disorders of the endometrium. Minerva Ginecol. 2006;58(6):511–526.
   PubMedGoogle Scholar
• Carvalho MJ, Laranjo M, Abrantes AM, et al. Clinical translation for endometrial cancer stem cells hypothesis. Cancer Metastasis Rev. 2015;34(3):401–416.
   PubMed Web of Science ®Google Scholar
• Piltonen TT, Chen J, Erikson DW, et al. Mesenchymal stem/progenitors and other endometrial cell types from women with polycystic ovary syndrome (PCOS) display inflammatory and oncogenic potential. J Clin Endocrinol Metab. 2013;98(9):3765–3775.
   PubMed Web of Science ®Google Scholar
• Linkov F, Kokai L, Edwards R, et al. The role of adipose-derived stem cells in endometrial cancer proliferation. Scand J Clin Lab Invest Suppl. 2014;244:54–58.
   PubMedGoogle Scholar
• Freese KE, Kokai L, Edwards RP, et al. Adipose-derived stems cells and their role in human cancer development, growth, progression, and metastasis: a systematic review. Cancer Res. 2015;75(7):1161–1168.
   PubMed Web of Science ®Google Scholar
• Rio MC, Dali-Youcef N, Tomasetto C. Local adipocyte cancer cell paracrine loop: can “sick fat” be more detrimental? Horm Mol Biol Clin Investig. 2015;21(1):43–56.
   PubMedGoogle Scholar
• Deshmukh-Rane SA, Wu ML. Pseudolipomatosis affects specimens from endometrial biopsies. Am J Clin Pathol. 2009;132(3):374–377.
   PubMed Web of Science ®Google Scholar
• Nogales FF, Pavcovich M, Medina MT, et al. Fatty change in the endometrium. Histopathology. 1992;20(4):362–363.
   PubMed Web of Science ®Google Scholar
• Klopp AH, Zhang Y, Solley T, et al. Omental adipose tissue-derived stromal cells promote vascularization and growth of endometrial tumors. Clin Cancer Res. 2012;18(3):771–782.
   PubMed Web of Science ®Google Scholar
• Nair S, Nguyen H, Salama S. Al-Hendy A obesity and the endometrium: adipocyte-secreted proinflammatory TNFα cytokine enhances the proliferation of human endometrial glandular cells. Obstet Gynecol Int. 2013;2013:368543.
   PubMedGoogle Scholar
• Cypess AM, White AP, Vernochet C, et al. Anatomical localization, gene expression profiling and functional characterization of adult human neck brown fat. Nat Med. 2013;19(5):635–639.
   PubMed Web of Science ®Google Scholar
• Kunkel SD, Elmore CJ, Bongers KS, et al. Ursolic acid increases skeletal muscle and brown fat and decreases diet-induced obesity, glucose intolerance and fatty liver disease. PLoS One. 2012;7(6):e39332.
   PubMed Web of Science ®Google Scholar
• Ortega-Molina A, Efeyan A, Lopez-Guadamillas E, et al. Pten positively regulates brown adipose function, energy expenditure, and longevity. Cell Metab. 2012;15(3):382–394.
   PubMed Web of Science ®Google Scholar
• Nedergaard J, Cannon B. The browning of white adipose tissue: some burning issues. Cell Metab. 2014;20(3):396–407.
   PubMed Web of Science ®Google Scholar
• Giordano A, Smorlesi A, Frontini A, et al. White, brown and pink adipocytes: the extraordinary plasticity of the adipose organ. Eur J Endocrinol. 2014;170(5):R159–R171.
   PubMed Web of Science ®Google Scholar
• Li S, Hu R, Wang C, et al. miR-22 inhibits proliferation and invasion in estrogen receptor α-positive endometrial endometrioid carcinomas cells. Mol Med Rep. 2014;9(6):2393–2399.
   PubMed Web of Science ®Google Scholar
• Ge Q, Brichard S, Yi X, et al. MicroRNAs as a new mechanism regulating adipose tissue inflammation in obesity and as a novel therapeutic strategy in the metabolic syndrome. J Immunol Res. 2014;2014:987285.
   PubMed Web of Science ®Google Scholar
• Sianou A, Galyfos G, Moragianni D, et al. The role of microRNAs in the pathogenesis of endometrial cancer: a systematic review. Arch Gynecol Obstet. 2015;292(2):271–282.
   PubMed Web of Science ®Google Scholar
• Westin SN, Ju Z, Broaddus RR, et al. PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients. Mol Oncol. 2015 May 16. DOI:10.1016/j.molonc.2015.04.014. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Berg A, Hoivik EA, Mjøs S, et al. Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. Oncotarget. 2015;6(2):1327–1339.
   PubMed Web of Science ®Google Scholar
• Setiawan VW, Haessler J, Schumacher F, et al. HNF1B and endometrial cancer risk: results from the PAGE study. PLoS One. 2012;7(1):e30390.
   PubMed Web of Science ®Google Scholar
• Chornokur G, Amankwah EK, Davis SN, et al. Variation in HNF1B and obesity may influence prostate cancer risk in African American men: a pilot study. Prostate Cancer. 2013;2013:384594.
   PubMedGoogle Scholar
• Lin Y, Berg AH, Iyengar P, et al. The hyperglycemia-induced inflammatory response in adipocytes: the role of reactive oxygen species. J Biol Chem. 2005;280(6):4617–4626.
   PubMed Web of Science ®Google Scholar
• Al-Aubaidy HA, Jelinek HF. Oxidative DNA damage and obesity in type 2 diabetes mellitus. Eur J Endocrinol. 2011;164(6):899–904.
   PubMed Web of Science ®Google Scholar
• Milić M, Kišan M, Rogulj D, et al. Level of primary DNA damage in the early stage of metabolic syndrome. Mutat Res. 2013;758(1–2):1–5.
   PubMed Web of Science ®Google Scholar
• Yuzefovych LV, Musiyenko SI, Wilson GL, et al. Mitochondrial DNA damage and dysfunction, and oxidative stress are associated with endoplasmic reticulum stress, protein degradation and apoptosis in high fat diet-induced insulin resistance mice. PLoS One. 2013;8(1):e54059.
   PubMed Web of Science ®Google Scholar
• Berstein L, Zimarina T, Imyanitov E, et al. Hormonal imbalance in two types of endometrial cancer and genetic polymorphism of steroidogenic enzymes. Maturitas. 2006;54(4):352–355.
   PubMed Web of Science ®Google Scholar
• McCourt CK, Mutch DG, Gibb RK, et al. Body mass index: relationship to clinical, pathologic and features of microsatellite instability in endometrial cancer. Gynecol Oncol. 2007;104(3):535–539.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang Y, Li J, et al. Lynch syndrome related endometrial cancer: clinical significance beyond the endometrium. J Hematol Oncol. 2013;6:22.
   PubMed Web of Science ®Google Scholar
• Amankwah EK, Friedenreich CM, Magliocco AM, et al. Anthropometric measures and the risk of endometrial cancer, overall and by tumor microsatellite status and histological subtype. Am J Epidemiol. 2013;177(12):1378–1387.
   PubMed Web of Science ®Google Scholar
• Dunn LJ, Bradbury JT. Endocrine factors in endometrial carcinoma. A preliminary report. Am J Obstet Gynecol. 1967;97(4):465–471.
   PubMed Web of Science ®Google Scholar
• Dilman VM, Berstein LM, Bobrov YF, et al. Hypothalamopituitary hyperactivity and endometrial carcinoma. Qualitative and quantitative disturbances in hormone production. Am J Obstet Gynecol. 1968;102(6):880–889.
   PubMed Web of Science ®Google Scholar
• Cantrell LA, Zhou C, Mendivil A, et al. Metformin is a potent inhibitor of endometrial cancer cell proliferation–implications for a novel treatment strategy. Gynecol Oncol. 2010;116(1):92–98.
   PubMed Web of Science ®Google Scholar
• Iglesias DA, Yates MS, Van Der Hoeven D, et al. Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy. Mol Cancer Ther. 2013;12(12):2847–2856.
   PubMed Web of Science ®Google Scholar
• Moore SC, Gierach GL, Schatzkin A, et al. Physical activity, sedentary behaviours, and the prevention of endometrial cancer. Br J Cancer. 2010;103(7):933–938.
   PubMed Web of Science ®Google Scholar
• Handgraaf S, Riant E, Fabre A, et al. Prevention of obesity and insulin resistance by estrogens requires ERα activation function-2 (ERαAF-2), whereas ERαAF-1 is dispensable. Diabetes. 2013;62(12):4098–4108.
   PubMed Web of Science ®Google Scholar
• Dalleck LC, Van Guilder GP, Richardson TB, et al. A community-based exercise intervention transitions metabolically abnormal obese adults to a metabolically healthy obese phenotype. Diabetes Metab Syndr Obes. 2014;7:369–380.
   PubMedGoogle Scholar